Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts

NCT05369975 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT05369975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05369975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts
Lead sponsor
Hansa Biopharma AB
Phase
Phase 3
Overall status
Completed
Start date
April 19, 2022
Completion date
April 21, 2026
Enrollment
113 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation in highly sensitized patients